All In Biotech

NDA 208612 · Avion Pharms

Balcoltra

Ethinyl Estradiol, Levonorgestrel · Oral

Last checked: Nov 20, 2026Latest source record: Apr 29, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Jan 9, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

501

113 Phase 3, 20 recruiting

FAERS reports

641

469 serious, 22 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke [ see Contraindications ( 4 )] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. Levonorgestrel and ethinyl estradiol tablets and ferrous bisglycinate tablets are contraindicated in women over 35 years old who smoke. ( 4 ) Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. ( 4 )

What it is approved for

From the label in effect Dec 5, 2025.

Levonorgestrel and ethinyl estradiol tablets, USP and ferrous bisglycinate tablets are indicated for use by females of reproductive potential to prevent pregnancy. Levonorgestrel and ethinyl estradiol tablets, USP and ferrous bisglycinate tablets are progestin/estrogen COC indicated for use by females of reproductive potential to prevent pregnancy. ( 1 )

Mechanism: COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BALCOLTRA · ETHINYL ESTRADIOL 0.02MG; LEVONORGESTREL 0.1MG · TABLET, ORAL · Prescription · TE AB3

Clinical trials

Interventional ClinicalTrials.gov studies with "Ethinyl Estradiol" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea47
  • headache45
  • dizziness37
  • drug ineffective36
  • fatigue34
  • vomiting33
  • dyspnoea27
  • pulmonary embolism27
  • anxiety25
  • malaise24
  • diarrhoea23
  • drug interaction22

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200421
200546
200619
200727
200816
200924
201027
201140
201236
20134
201410
201514
201621
201726
201820
201951
202047
202142
202227
202339
202426
202538
202620

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Balcoltra (Levonorgest/Eth.Estradiol/Iron)

2024 spending

$15K

Beneficiaries

12

36 claims

Per beneficiary

$1,280

$9.46 per unit

View as table
YearSpending
2020$12,949
2021$32,971
2022$43,090
2023$38,802
2024$15,360

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,068 on PubMed

Sponsor: Avion Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.